Baseimmune Secures £9M Series A Funding to Advance AI-driven Vaccine Development
The newly secured capital will facilitate the acceleration of Baseimmune's vaccine development programs, including candidates for African swine fever.
London-based biotech startup Baseimmune has closed an impressive £9 million Series A funding round to propel its pioneering work in AI-driven vaccine design. Led by MSD Global Health Innovation Fund and IQ Capital, with continued support from existing investors, this oversubscribed financing underscores the growing importance of technology in combating infectious diseases.
Founded in 2019, Baseimmune harnesses the power of proprietary deep learning algorithms to forecast pathogen mutations and engineer synthetic antigen proteins. With a foundation in computational approaches developed at the Jenner Institute, University of Oxford, Baseimmune is poised to make significant strides in vaccine innovation and disease prevention.
CEO & Co-Founder of Baseimmune, Joshua Blight, expressed enthusiasm for the support from leading investors, highlighting the potential of the funding to accelerate the development of impactful vaccines against future viruses. The company remains committed to disrupting pandemic readiness and addressing global health challenges.
The newly secured capital will facilitate the acceleration of Baseimmune's vaccine development programs, including candidates for African swine fever, coronavirus, and malaria, which are currently in preclinical development. Additionally, the funding will fuel technological advancements, team expansion, and the initiation of new vaccine programs.
Baseimmune's innovative vaccine design algorithm combines genomic, epidemiological, immunological, clinical, and evolutionary data to create synthetic antigenic proteins that evoke a strong protective immune response. This computational platform enables the rapid development of vaccine candidates, with designs compatible with various vaccine technology platforms, such as mRNA, DNA, and viral vectors.
David M. Rubin, Managing Director of MSD Global Health Innovation Fund, emphasized the advancement represented by Baseimmune's technology in proactive and adaptable vaccine solutions. The forward-looking approach of Baseimmune's team has garnered support from investors eager to contribute to the development of universal vaccines.
